Del Mar, CA, October 05, 2024 — OcuSci Inc., a leader in ophthalmic innovation, recently announced the granting of a second utility patent for the MGrx Dry Eye Treatment System. US patent # US2023/0100143A1 adds to OcuSci’s substantial intellectual property portfolio in the area of dry eye treatments.
The MGrx System represents a significant advancement in dry eye management, offering a novel approach to alleviating symptoms and addressing the underlying causes of the condition. Dry eye syndrome affects millions globally, leading to discomfort, irritation, and even vision impairment. Traditional treatments often fall short in providing long-lasting relief, which underscores the need for innovative solutions.
“We are thrilled to receive this patent, which recognizes the uniqueness and effectiveness of our dry eye treatment,” said David McMahon, CEO of OcuSci. “Additionally, due to the fact that our technology requires no disposables or per treatment costs we are able to make affordable in-clinic dry eye treatment a reality for millions of patients suffering from dry eye syndrome.”
The patented technology utilizes a proprietary mechanism designed to enhance meibomian gland function and lipid production, providing a comprehensive solution for dry eye sufferers. Published clinical trials have demonstrated significant improvements in symptom relief and patient satisfaction.
Key features of the patented treatment include:
Tri-modal Design: enabling clinicians to deliver three effective treatments all with one battery powered hand-held device.
Cost Effective: the MGrx requires no disposables or per treatment costs.
Patient-Friendly Application: designed for patient comfort and ease of use.
This patent achievement is expected to pave the way for future developments and enhancements in eye care, reinforcing OcuSci’s dedication to improving patient outcomes.